Skip to content
  • Sunday, 26 July 2026
  • 3:07 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis
Pharmaceutical R&D

Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis

Teuku Ryan Jun 16, 2026 0

Simcere Pharmaceutical Group has forged a significant research collaboration with Stanford Medicine, aiming to unlock novel therapeutic avenues for idiopathic…

Read More
Pharmaceutical R&D

Japan Approves Jascayd (nerandomilast) for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Teuku Ryan May 19, 2026 0

Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…

Read More
Biotech & Genetic Research

AI-Powered "GPS" Model Marks Paradigm Shift in Drug Discovery, Identifies Candidates for Liver Cancer and Pulmonary Fibrosis

Jia Lissa Apr 11, 2026 0

A groundbreaking machine-learning model, dubbed "GPS" (Gene Expression Profile Predictor on Chemical Structures), has been unveiled by a multi-institute collaboration…

Read More
Pharmaceutical R&D

New Data at ACC 2026 Illuminates Sotatercept’s Transformative Role in Pulmonary Arterial Hypertension Treatment Regimens

Teuku Ryan Apr 3, 2026 0

New insights unveiled at the American College of Cardiology (ACC) Annual Scientific Session & Expo 2026 are poised to reshape…

Read More
Pharmaceutical R&D Returns Soar to 7% Driven by GLP-1 Blockbusters, Raising Sustainability Questions for the IndustryThe Findings Support the Idea That Water Pervades the Galaxy’s Planet-Building MaterialTWiV 1289: Building a better hepatitis B trapThe Oxygen Theory Behind Giant Insects of the Carboniferous Period Is Being Re-examined
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ